Clinical Trial Update: Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating oral vorinostat (SAHA) for advanced cutaneous T-cell lymphoma, including Sézary syndrome and mycosis fungoides, sponsored by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• Zolinza (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cutaneous T-cell Lymphoma, Sezary Syndrome | Phase 2 | Status: COMPLETED